Report presenting the National Security Commission on Artificial Intelligence's initial (NSCAI)'s preliminary assessment of artificial intelligence (AI). It discusses NSCAI's definition of AI, the challenges and context around it, where the U.S. Government can apply it, considerations on ethical and trustworhy AI, and associated technologies.

A brief report summarizing the National Security Commission on Artificial Intelligence's activities, meetings, relationships with the U.S. Government, industry, and academia, early substantive assessments, commission staff, and next steps.

Artificial intelligence and machine learning (AI/ML) is a set of technologies that includes automated systems able to perform tasks that normally require human intelligence, such as visual perception, speech recognition, and decision-making. AI/ML has promising applications in health care, including drug development. For example, it may have the potential to help identify new treatments, reduce failure rates in clinical trials, and generally result in a more efficient and effective drug development process. However, applying AI/ML technologies within the health care system also raises ethical, legal, economic, and social questions. GAO was asked to conduct a technology assessment on the use of AI technologies in drug development with an emphasis on foresight and policy implications. This report discusses (1) current and emerging AI technologies available for drug development and their potential benefits; (2) challenges to the development and adoption of these technologies; and (3) policy options to address challenges to the use of machine learning in drug development. -- from Foreword